The Global Large And Small-scale Bioprocessing Market size is expected to reach $159.6 billion by 2030, rising at a market growth of 14.2% CAGR during the forecast period.
The biopharmaceutical industry's expansion has spurred continuous advancements in bioprocessing technologies. Therefore, Biopharmaceuticals segment would generate $35,141.7 million revenue in the market in 2022. As a result, the constant innovation within the biopharmaceutical industry has a positive feedback loop, driving the evolution of bioprocessing technologies and equipment. As biopharmaceutical companies strive to optimize their manufacturing processes, they invest in cutting-edge equipment, automation, and process control systems.
The major strategies followed by the market participants are Geographical Expansion as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2022, Eppendorf Group expanded its Jülich bioprocess site by constructing a new multifunctional building. Moreover, In April, 2022, Thermo Fisher Scientific set up a new single-use technology manufacturing site in Ogden, Utah, enhancing capacity for high-quality materials crucial in developing vaccines and therapies. This expansion strengthens the company's Utah presence and facilitates close collaboration with the Logan site, tapping into a skilled workforce for manufacturing intricate, customized solutions.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., GE healthcare, Corning Incorporated, Sartorius AG, Lonza Group AG (Capsugel), Meissner Filtration Products, Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd. and Eppendorf SE.
The biopharmaceutical industry's expansion has spurred continuous advancements in bioprocessing technologies. Therefore, Biopharmaceuticals segment would generate $35,141.7 million revenue in the market in 2022. As a result, the constant innovation within the biopharmaceutical industry has a positive feedback loop, driving the evolution of bioprocessing technologies and equipment. As biopharmaceutical companies strive to optimize their manufacturing processes, they invest in cutting-edge equipment, automation, and process control systems.
The major strategies followed by the market participants are Geographical Expansion as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2022, Eppendorf Group expanded its Jülich bioprocess site by constructing a new multifunctional building. Moreover, In April, 2022, Thermo Fisher Scientific set up a new single-use technology manufacturing site in Ogden, Utah, enhancing capacity for high-quality materials crucial in developing vaccines and therapies. This expansion strengthens the company's Utah presence and facilitates close collaboration with the Logan site, tapping into a skilled workforce for manufacturing intricate, customized solutions.
Cardinal Matrix
Market Competition Analysis
Based on the Analysis presented in the Cardinal Matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Market. Companies such as Merck KGaA, Thermo Fisher Scientific, Inc., and Boehringer Ingelheim International GmbH are some of the key innovators in the Market. In July, 2023, Sartorius AG expanded its site in Yauco, Puerto Rico, by incorporating a new cell culture media manufacturing facility. This addition solidified their extensive portfolio, particularly catering to customers in the Americas.
COVID-19 Impact Analysis
The pandemic led to an urgent need for COVID-19 vaccines, which required rapidly scaling up large-scale bioprocessing facilities. This resulted in increased demand for bioprocessing equipment, single-use technologies, and expertise in large-scale vaccine production. The pandemic prompted increased funding for research, including small-scale bioprocessing activities related to developing diagnostics, therapeutics, and vaccines. Academic and research labs received substantial funding for COVID-19-related projects. Many small-scale bioprocessing labs shifted to remote work and virtual collaboration to comply with social distancing measures. This accelerated the adoption of digital tools and software for data analysis, experiment planning, and communication. Therefore, COVID-19 impact had an overall positive effect on the market.Market Growth Factors
Rising demand for biosimilars, generic biologics, and personalized medicine
The demand for biosimilars and generic biologics, driven by the expiration of patents on biologic drugs, has significantly impacted the large-scale bioprocessing. Biosimilars and generic biologics aim to provide more affordable alternatives to biologic drugs, making them more accessible to patients. To meet this growing demand, large-scale bioprocessing facilities are required to produce these biologics efficiently and cost-effectively. As a result, the large-scale bioprocessing businesses have seen a boost in activity, with increased investment in production facilities and equipment. Therefore, the increasing demand for these pharmaceuticals is propelling the growth of the market.Advancements in bioprocessing technologies
Continuous advancements in bioprocessing equipment, automation, and analytics improve the efficiency and scalability of large-scale production. Single-use bioprocessing equipment and systems have become increasingly popular in large-scale bioprocessing. These systems eliminate the need for cleaning and sterilization, reducing downtime and the risk of contamination. Continuous bioprocessing is gaining traction as an alternative to traditional batch processing. Automated high-throughput screening technologies help rapidly screen cell lines, culture conditions, and process parameters, accelerating process development for large-scale production. Advancements in bioprocessing technologies have significantly impacted the market.Market Restraining Factors
Stringent regulatory compliance
Small-scale bioprocessing labs, especially in academic or startup settings, have limited resources and expertise to navigate complex regulatory requirements. Establishing and maintaining quality systems, including standard operating procedures (SOPs) and documentation, can be challenging for smaller organizations with fewer personnel. Transitioning from small-scale to larger-scale production while maintaining compliance can be difficult, especially when processes and equipment need to be adapted. Thus, regulatory compliance is a significant challenge in large and small-scale bioprocessing market.Scale Outlook
By scale, the market is categorized into industrial scale and small scale. In 2022, the industrial scale segment held the highest revenue share in the market. Large-scale bioprocessing at volumes exceeding 50,000 litres is often associated with producing monoclonal antibodies, vaccines, and other biopharmaceuticals. These products require large quantities to meet global demand. Due to their durability and capacity to endure high pressures and volumes, stainless steel bioreactors are frequently used in large-scale bioprocessing facilities.Workflow Outlook
Based on workflow, the market is classified into downstream processing, fermentation, and upstream processing. The fermentation segment acquired a substantial revenue share in the market in 2022. Large-scale fermentation allows the production of substantial quantities of products. Large-scale fermentation processes often benefit from economies of scale, resulting in lower production costs per product unit. This is critical for cost-effective manufacturing of biopharmaceuticals and other high-value products. Large-scale fermenters have advanced monitoring and control systems to ensure consistent product quality.
Use Type Outlook
Based on use type, the market is fragmented into multi use and single use. The single use segment covered a considerable revenue share in the market in 2022. Single use systems are highly adaptable and readily scaled to accommodate fluctuating production requirements. This scalability is valuable for large and small-scale bioprocessing operations, allowing them to adapt to evolving market demands. Single-use systems can reduce downtime associated with cleaning, sterilization, and changeover between batches. This results in faster turnaround times, making it easier to quickly meet production schedules and respond to market demands.Mode Outlook
On the basis of mode, the market is bifurcated into in-house and outsourced. The outsourced segment acquired a substantial revenue share in the large and small-scale bioprocessing market in 2022. Large pharmaceutical and biotechnology companies outsource bioprocessing to contract manufacturing organizations (CMOs) to produce biopharmaceuticals. CMOs have the infrastructure and expertise to scale up production quickly to meet high demand. CMOs often specialize in certain types of bioprocessing, such as monoclonal antibody production or vaccine manufacturing. Large-scale companies can benefit from these service providers' specialized knowledge and experience. Small biotech startups and research institutions lack the specialized equipment and facilities for certain bioprocessing activities. Outsourcing provides access to advanced equipment and infrastructure.Application Outlook
By application, the market is segmented into biopharmaceuticals, speciality industrial chemicals, and environmental aids. In 2022, the biopharmaceuticals segment registered the maximum revenue share in the market. The primary application of bioprocessing is the commercial production of biopharmaceuticals for the market. This includes manufacturing large quantities of monoclonal antibodies, vaccines, recombinant proteins, and other biologics. Monoclonal antibodies are widely used to treat cancer, autoimmune diseases, and infectious diseases. Many biopharmaceutical companies outsource the large-scale production of their products to contract manufacturing organizations (CMOs).Product Outlook
On the basis of product, the market is divided into bioreactors/fermenters, cell culture products, filtration assemblies, bioreactors accessories, bags & containers, and others. In 2022, the bioreactors/fermenters segment dominated the market with maximum revenue share. Large-scale biopharmaceutical manufacturing facilities typically employ stainless steel bioreactors. These bioreactors are designed for high-volume production and are known for their durability, sterility, and ability to withstand high pressure and temperature conditions. There has been a growing trend in large-scale bioprocessing towards adopting single-use bioreactors. These systems offer flexibility, reduce the risk of contamination, and minimize the need for time-consuming cleaning and sterilization processes.Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. North America is home to numerous large pharmaceutical and biotechnology companies that use large-scale bioprocessing to produce biopharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and more. North America boasts state-of-the-art biomanufacturing facilities with large-scale bioreactors, downstream processing units, and quality control systems. North America, particularly the United States, has a thriving ecosystem of biotech startups that engage in small-scale bioprocessing for research, development, and early-stage product testing.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., GE healthcare, Corning Incorporated, Sartorius AG, Lonza Group AG (Capsugel), Meissner Filtration Products, Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd. and Eppendorf SE.
Strategies deployed in the Market
Partnerships, Collaborations, and Agreements:
- Oct-2023: Boehringer Ingelheim International GmbH collaborated with ZEISS Medical Technology, a multinational medical technology company and subsidiary of Carl Zeiss AG, to develop predictive analytics for the early detection of eye diseases and personalized treatments to prevent vision loss. The partnership, which brought together their expertise in ophthalmological technology, data analytics, algorithms, and first-in-class treatments, aimed to detect and treat retinal diseases early, preventing irreversible vision loss.
- May-2023: Merck KGaA had signed a non-binding MoU with Ministry of Trade, Industry and Energy (MOTIE) and Daejeon City for an Asia-Pacific BioProcessing Center. The facility, aimed at aiding the region's healthcare ecosystem, would support commercial manufacturing for biotech and pharmaceutical clients in Asia-Pacific, serving as a vital hub for industry development in South Korea.
- Apr-2023: Sartorius AG came into partnership with va-Q-tec, an innovator in thermal insulation solutions, to enhance logistics for shipping bulk drug substances (BDS). As BDS are highly temperature-sensitive and valuable, this collaboration seeks to improve efficiency and safety in their transportation within the industry. The partnership built on years of collaboration, leveraging the established positions and expertise of both Sartorius and va-Q-tec in the field.
- Jan-2023: Sartorius AG extended collaboration with RoosterBio Inc., a privately held cell manufacturing platform technology company, to tackle purification challenges and set up scalable downstream manufacturing for exosome-based therapies. The partnership aimed to deliver high-quality solutions for an hMSC-based exosome production platform, emphasizing top-tier yield, purity, and potency. The collaboration also focused on developing comprehensive analytical techniques for characterizing exosomes and the entire range of extracellular vesicles (EVs), establishing quantitative strategies for quality control in exosome purification intermediates and final drug products.
Product Launches and Product Expansions:
- Sep-2022: Thermo Fisher Scientific, Inc. introduced the Thermo Scientific DynaSpin Single-Use Centrifuge system, designed for large-scale cell culture harvesting. Streamlining the process in single-use bioprocessing, it reduces the required depth filtration cartridges, maintaining or improving product yield compared to traditional systems. The DynaSpin solution enhances operational efficiency, cost-effectiveness, and sustainability in biologics production.
Acquisition and Mergers:
- Jun-2023: Merck KGaA completed the acquisition of Prometheus Biosciences, Inc., making it a wholly owned subsidiary. Under the acquisition, Prometheus' common stock ceased trading on the Nasdaq Global Market, furthering Merck's presence in immunology, enhancing their pipeline, and strengthening their ability to provide patient value. This strategic and decisive move aligned with Merck's commitment to science and value.
- Dec-2022: Merck KGaA acquired Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology known as "Breez”, to enhance its therapeutic protein upstream portfolio with the "Breez" 2 ml micro-bioreactor platform. This supports scalable cell-based perfusion bioreactor processes from 2 mL to 2000L, aiding rapid lab-scale development. The acquisition also opens possibilities for future development in novel applications, including cell therapies.
- Apr-2022: Merck KGaA acquired the MAST (Modular Automated Sampling Technology) platform from Lonza to enhance its bioprocessing portfolio. Merck utilized the MAST platform, an automated, aseptic bioreactor sampling system developed in Bend, Oregon, USA. This technology, along with data analysis and management software, enabled Merck to provide distinctive and integrated solutions, assisting customers in optimizing their bioprocesses.
Geographical Expansions:
- Jul-2023: Sartorius AG expanded its site in Yauco, Puerto Rico, by incorporating a new cell culture media manufacturing facility. Now officially opened, this 21,500-square-foot (2,000 square meters) facility aimed to enhance the company's cell culture media capacities, with a specific focus on serving customers in the Americas region. This addition solidified their extensive portfolio, particularly catering to customers in the Americas.
- May-2023: Thermo Fisher Scientific, Inc. broadened its sterile manufacturing and research capabilities in the Asia-Pacific by inaugurating a new sterile drug facility in Singapore. Supported by the Singapore Economic Development Board, this good manufacturing practices facility complements Thermo Fisher's existing bioprocess design and customer experience centers, enhancing their operational labs with cutting-edge life science, analytical, and bioprocessing technologies.
- Sep-2022: Eppendorf Group expanded its Julich bioprocess site by constructing a new multifunctional building. The added space increased DASGIP Information and Process Technology GmbH's production capacity by up to 20%, showcasing Eppendorf's long-term commitment to its Julich production location.
- Apr-2022: Thermo Fisher Scientific set up a new single-use technology manufacturing site in Ogden, Utah, enhancing capacity for high-quality materials crucial in developing vaccines and therapies. This expansion strengthens the company's Utah presence and facilitates close collaboration with the Logan site, tapping into a skilled workforce for manufacturing intricate, customized solutions.
- Nov-2021: Lonza Group AG expanded its manufacturing capacity to enhance microbial development capabilities in Switzerland, by expanding laboratory space and equipment to increase capacity for development services focusing on microbial-derived proteins. This extension supports new projects in Lonza's existing manufacturing assets and complements the previously announced mid-scale microbial capacity expansion. Strengthening upstream, downstream, and process analytics support, these expanded development services address the complexities of manufacturing processes in microbial expression systems.
- Sep-2021: Sartorius AG expanded its Michigan presence by opening a 130,000-square-foot facility in Ann Arbor. The center of excellence consolidated operations in Washtenaw County for laboratory and Bioprocess products and services in North America. The focus is on delivering innovative solutions to aid customers in developing drugs to cure, prevent, and halt diseases.
- May-2021: Lonza Group AG expanded its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US). The expansion in Visp included a new large-scale facility with six 20,000L bioreactors to address the growing demand for biologics. Encompassing approximately 27,500 m2, the state-of-the-art facility, equipped with perfusion capabilities, was designed for high-titer processes and the next generation of mammalian biologics.
- Sep-2020: Thermo Fisher Scientific Inc. opened the Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri, located near its expanded biologics manufacturing facility. The BCC, merging expertise from Thermo Fisher's bioproduction and pharma services, aimed to boost innovation and productivity for biopharma companies. This initiative responds to the increasing demand for flexible, scalable solutions in biologics development and manufacturing, improving workflows and expediting product launches for customers.
Scope of the Study
Market Segments Covered in the Report:
By Scale- Industrial Scale
- Small Scale
- Multi Use
- Single Use
- In-house
- Outsourced
- Biopharmaceuticals
- Speciality Industrial Chemicals
- Environmental Aids
- Downstream Processing
- Fermentation
- Upstream Processing
- Bioreactors/Fermenters
- Cell Culture Products
- Filtration Assemblies
- Bioreactors Accessories
- Bags & Containers
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- GE healthcare
- Corning Incorporated
- Sartorius AG
- Lonza Group AG (Capsugel)
- Meissner Filtration Products, Inc.
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd.
- Eppendorf SE
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Global Large And Small-scale Bioprocessing Market by Scale
Chapter 6. Global Large And Small-scale Bioprocessing Market by Use Type
Chapter 7. Global Large And Small-scale Bioprocessing Market by Mode
Chapter 8. Global Large And Small-scale Bioprocessing Market by Application
Chapter 9. Global Large And Small-scale Bioprocessing Market by Workflow
Chapter 10. Global Large And Small-scale Bioprocessing Market by Product
Chapter 11. Global Large And Small-scale Bioprocessing Market by Region
Chapter 12. Company Profiles
Companies Mentioned
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- GE healthcare
- Corning Incorporated
- Sartorius AG
- Lonza Group AG (Capsugel)
- Meissner Filtration Products, Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Eppendorf SE
Methodology
LOADING...
